


What is claimed is:

1. A method of preventing or treating atherosclerosis or restenosis in a mammal, comprising administering to said mammal an effective amount of a compound selected from the group consisting of structure Formula VI, Formula VII, Formula VIII and Formula IX,

wherein Formula VI is:



or a pharmaceutically acceptable salt thereof wherein, A^{VI} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO_2 , or
- e) F;

R^{VI-1} is

- a) R^{VI-5} , or
- b) SO_2R^{VI-9}

R^{VI-2} , R^{VI-3} and R^{VI-4} may be the same or different and are selected from the group consisting of:

- a) H,
- b) halo^{VI},
- c) aryl^{VI},
- d) $S(O)_mR^{VI-6}$,
- e) $(C=O)R^{VI-6}$,
- f) $(C=O)OR^{VI-9}$,
- g) cyano,

- h) het^{VI} , wherein said het^{VI} is bound via a carbon atom,
- i) $\text{OR}^{\text{VI}-10}$,
- j) Ohet^{VI} ,
- k) $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$
- l) $\text{SR}^{\text{VI}-10}$,
- m) Shet^{VI} ,
- n) $\text{NHCOR}^{\text{VI}-12}$,
- o) $\text{NHSO}_2\text{R}^{\text{VI}-12}$,
- p) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{VI}-11}$, $\text{OR}^{\text{VI}-13}$, $\text{SR}^{\text{VI}-10}$, $\text{SR}^{\text{VI}-13}$, $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}\text{alkyl}$, or $\text{SO}_m\text{R}^{\text{VI}-9}$, and
- q) $\text{R}^{\text{VI}-3}$ together with $\text{R}^{\text{VI}-2}$ or $\text{R}^{\text{VI}-4}$ form a carbocyclic or $^{\text{VI}}\text{-het}$ which may be optionally substituted by $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, or $\text{C}_{1-7}\text{alkyl}$ which may be optionally substituted by $\text{OR}^{\text{VI}-14}$;

$\text{R}^{\text{VI}-5}$ is

- a) $(\text{CH}_2\text{CH}_2\text{O})_i\text{R}^{\text{VI}-10}$,
- b) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, $\text{R}^{\text{VI}-11}$, $\text{SO}_m\text{R}^{\text{VI}-9}$, or $\text{OC}_{2-4}\text{alkyl}$ which may be further substituted by het^{VI} , $\text{OR}^{\text{VI}-10}$, or $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, or
- c) $\text{C}_{3-8}\text{cycloalkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of $\text{R}^{\text{VI}-11}$, $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, $\text{SO}_m\text{R}^{\text{VI}-9}$, or $\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{R}^{\text{VI}-11}$, $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, or $\text{SO}_m\text{R}^{\text{VI}-9}$;

$\text{R}^{\text{VI}-6}$ is

- a) $\text{C}_{1-7}\text{alkyl}$,
- b) $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$,

- c) aryl^{VI}, or
- d) het^{VI}, wherein said het^{VI} is bound via a carbon atom;

R^{VI-7} and R^{VI-8} are independently

- a) H,
- b) aryl^{VI},
- c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of aryl^{VI}, NR^{VI-10}R^{VI-10}, R^{VI-11}, SO_mR^{VI-9}, CONR^{VI-10}R^{VI-10}, or halo, or;
- d) C₃₋₈cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of R^{VI-11}, NR^{VI-7}R^{VI-8}, SO_mR^{VI-9}, or C₁₋₇alkyl optionally substituted by R^{VI-11}, NR^{VI-7}R^{VI-8}, or SO_mR^{VI-9}, or
- e) R^{VI-7} and R^{VI-8} together with the nitrogen to which they are attached form a het^{VI};

R^{VI-9} is

- a) aryl^{VI},
- b) het^{VI},
- c) C₃₋₈cycloalkyl,
- d) methyl, or
- e) C₂₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of NR^{VI-10}R^{VI-10}, R^{VI-11}, SH, CONR^{VI-10}R^{VI-10}, or halo;

R^{VI-10} is

- a) H,
- b) methyl, or
- c) C₂₋₇alkyl optionally substituted by OH;

R^{VI-11} is

- a) OR^{VI-10},
- b) Ohet^{VI},

- c) Oaryl^{VI} ,
- d) $\text{CO}_2\text{R}^{\text{VI}-10}$,
- e) het^{VI} ,
- f) $^{\text{VI}}\text{-aryl}^{\text{VI}}$,
- g) CN , or
- h) $\text{C}_{3-8}\text{cycloalkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of $\text{R}^{\text{VI}-11}$, $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, $\text{SO}_m^{\text{IV}}\text{R}^{\text{VI}-9}$, or $\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{R}^{\text{VI}-11}$, $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, or $\text{SO}_m\text{R}^{\text{VI}-9}$;

$\text{R}^{\text{VI}-12}$ is

- a) H ,
- b) het^{VI} ,
- c) aryl^{VI} ,
- d) $\text{C}_{3-8}\text{cycloalkyl}$,
- e) methyl , or
- f) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$ or $\text{R}^{\text{VI}-11}$;

$\text{R}^{\text{VI}-13}$ is

- a) $(\text{P}=\text{O})(\text{OR}^{\text{VI}-14})_2$,
- b) $\text{CO}(\text{CH}_2)_n^{\text{IV}}\text{CON}(\text{CH}_3)-(\text{CH}_2)_n\text{SO}_3^-\text{M}^{\text{VI}+}$,
- c) an amino^{VI} acid,
- d) $\text{C}(=\text{O})\text{aryl}^{\text{VI}}$,
- e) $\text{C}(=\text{O})\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$, aryl^{VI} , het^{VI} , CO_2H , or $\text{O}(\text{CH}_2)_n\text{CO}_2\text{R}^{\text{VI}-14}$, or
- f) $\text{C}(=\text{O})\text{NR}^{\text{VI}-7}\text{R}^{\text{VI}-8}$

$\text{R}^{\text{VI}-14}$ is

- a) H , or
- b) $\text{C}_{1-7}\text{alkyl}$;

each i^{VI} is independently 2, 3, or 4;

each n^{VI} is independently 1, 2, 3, 4 or 5;

each m^{VI} is independently 0, 1, or 2;

M^{VI} is sodium, potassium, or lithium;

aryl^{VI} is a phenyl radical or an ortho-fused bicyclic


carbocyclic radical wherein at least one ring is aromatic;

wherein any aryl^{VI} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, CO₂R^{VI-14}, CF₃, C₁₋₆alkoxy, and C₁₋₆ alkyl which maybe further substituted by one to three SR^{VI-14}, NR^{VI-14}R^{VI-14}, OR^{VI-14}, or CO₂R^{VI-14};

het^{VI} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{VI} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO₂R^{VI-14}, CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆ alkyl which maybe further substituted by one to three SR^{VI-14}, NR^{VI-14}R^{VI-14}, OR^{VI-14}, or CO₂R^{VI-14};

wherein Formula VII is



VII

or a pharmaceutically acceptable salt thereof,

wherein

A^{VII} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO₂, or
- e) F;

R^{VII-1} is

- a) aryl^{VII},
- b) $S(O)_m^{VII}R^{VII-6}$,
- c) $(C=O)R^{VII-6}$, with the proviso that if R^{VII-6} is $NR^{VII-7}R^{VII-8}$, then R^{VII-7} and R^{VII-8} do not both equal H,
- d) $(C=O)OR^{VII-9}$,
- e) cyano,
- f) het^{VII}, wherein said het^{VII} is bound via a carbon atom,
- g) Ohet^{VII},
- h) $NR^{VII-7}R^{VII-8}$ with the proviso that R^{VII-7} and R^{VII-8} do not both equal H,
- i) SR^{VII-10} ,
- j) Shet^{VII},
- k) $NHCOR^{VII-12}$,
- l) $NHSO_2R^{VII-12}$,
- m) C_{1-7} alkyl which is partially unsaturated and optionally substituted by one or more substituents of the group R^{VII-11} , OR^{VII-13} , SR^{VII-10} , SR^{VII-13} , $NR^{VII-7}R^{VII-8}$, halo, $(C=O)C_{1-7}$ alkyl, or SO_mR^{VII-9} , or
- n) C_{1-7} alkyl which is substituted by one or more substituents of the group R^{VII-11} , OR^{VII-13} , SR^{VII-10} , SR^{VII-13} , $NR^{VII-7}R^{VII-8}$, halo, $(C=O)C_{1-7}$ alkyl, or $SO_m^{VII}R^{VII-9}$;

R^{VII-2} is

- a) H,
- b) halo,
- c) aryl^{VII},
- d) $S(O)_m^{VII}R^{VII-6}$,
- e) $(C=O)R^{VII-6}$,
- f) $(C=O)OR^{VII-9}$,
- g) cyano,

- h) het^{VII} , wherein said het^{VII} is bound via a carbon atom,
- i) $\text{OR}^{\text{VII-10}}$,
- j) Ohet^{VII} ,
- k) $\text{NR}^{\text{VII-7}}\text{R}^{\text{VII-8}}$,
- l) $\text{SR}^{\text{VII-10}}$,
- m) Shet^{VII} ,
- n) $\text{NHCOR}^{\text{VII-12}}$,
- o) $\text{NHSO}_2\text{R}^{\text{VII-12}}$, or
- p) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{VII-11}}$, $\text{OR}^{\text{VII-13}}$, $\text{SR}^{\text{VII-10}}$, $\text{SR}^{\text{VII-13}}$, $\text{NR}^{\text{VII-7}}\text{R}^{\text{VII-8}}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}\text{alkyl}$, or $\text{SO}_m^{\text{VII}}\text{R}^{\text{VII-9}}$, or
- q) $\text{R}^{\text{VII-1}}$ together with $\text{R}^{\text{VII-2}}$ form a carbocyclic or het^{VII} which may be optionally substituted by $\text{NR}^{\text{VII-7}}\text{R}^{\text{VII-8}}$, or $\text{C}_{1-7}\text{alkyl}$ which may be optionally substituted by $\text{OR}^{\text{VII-14}}$;

$\text{R}^{\text{VII-6}}$ is

- a) $\text{C}_{1-7}\text{alkyl}$,
- b) $\text{NR}^{\text{VII-7}}\text{R}^{\text{VII-8}}$
- c) aryl^{VII} , or
- d) het^{VII} , wherein said het^{VII} is bound via a carbon atom;

$\text{R}^{\text{VII-7}}$ and $\text{R}^{\text{VII-8}}$ are independently

- a) H,
- b) aryl^{VII} ,
- c) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{VII-10}}\text{R}^{\text{VII-10}}$, $\text{R}^{\text{VII-11}}$, $\text{SO}_m\text{R}^{\text{VII-9}}$, $\text{CONR}^{\text{VII-10}}\text{R}^{\text{VII-10}}$, or halo, or,
- d) $\text{R}^{\text{VII-7}}$ and $\text{R}^{\text{VII-8}}$ together with the nitrogen to which they are attached form a het^{VII} ;

$\text{R}^{\text{VII-9}}$ is

- a) aryl^{VII} ,

- b) het^{VII} ,
- c) $\text{C}_{3-8}\text{cycloalkyl}$,
- d) methyl, or
- e) $\text{C}_{2-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{VII}-10}\text{R}^{\text{VII}-10}$, $\text{R}^{\text{VII}-11}$, SH , $\text{CONR}^{\text{VII}-10}\text{R}^{\text{VII}-10}$, or halo;

$\text{R}^{\text{VII}-10}$ is

- a) H,
- b) methyl, or
- c) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by OH;

$\text{R}^{\text{VII}-11}$ is

- a) $\text{OR}^{\text{VII}-10}$,
- b) Ohet^{VII} ,
- c) $\text{Oaryl}^{\text{VII}}$,
- d) $\text{CO}_2\text{R}^{\text{VII}-10}$,
- e) het^{VII} ,
- f) aryl^{VII} ,
- g) CN, or
- h) $\text{C}_{3-8}\text{cycloalkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of $\text{R}^{\text{VII}-11}$, $\text{NR}^{\text{VII}-7}\text{R}^{\text{VII}-8}$, $\text{SO}_m^{\text{VII}}\text{R}^{\text{VII}-9}$, or $\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{R}^{\text{VII}-11}$, $\text{NR}^{\text{VII}-7}\text{R}^{\text{VII}-8}$, or $\text{SO}_m\text{R}^{\text{VII}-9}$;

$\text{R}^{\text{VII}-12}$ is

- a) H,
- b) het^{VII} ,
- c) aryl^{VII} ,
- d) $\text{C}_{3-8}\text{cycloalkyl}$,
- e) methyl, or
- f) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VII}-7}\text{R}^{\text{VII}-8}$ or $\text{R}^{\text{VII}-11}$;

$\text{R}^{\text{VII}-13}$ is

- a) $(\text{P}=\text{O})(\text{OR}^{\text{VII}-14})_2$,

- b) $\text{CO}(\text{CH}_2)_n\text{CON}(\text{CH}_3) - (\text{CH}_2)_n\text{SO}_3^-\text{M}^+$,
- c) an amino acid,
- d) $\text{C}(=\text{O})\text{aryl}^{\text{VII}}$, or
- e) $\text{C}(=\text{O})\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VII}-7}\text{R}^{\text{VII}-8}$, aryl^{VII} , het^{VII} , CO_2H , or $\text{O}(\text{CH}_2)_n^{\text{VII}}\text{CO}_2\text{R}^{\text{VII}-14}$;

$\text{R}^{\text{VII}-14}$ is

- a) H, or
- b) $\text{C}_{1-7}\text{alkyl}$;

each n^{VII} is independently 1, 2, 3, 4 or 5;

each m^{VII} is independently 0, 1, or 2;

M^{VII} is sodium, potassium, or lithium;


aryl^{VII} is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

wherein any aryl^{VII} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, $\text{CO}_2\text{R}^{\text{VII}-14}$, CF_3 , $\text{C}_{1-6}\text{alkoxy}$, and $\text{C}_{1-6}\text{alkyl}$ which may be further substituted by one to three $\text{SR}^{\text{VII}-14}$, $\text{NR}^{\text{VII}-14}\text{R}^{\text{VII}-14}$, $\text{OR}^{\text{VII}-14}$, or $\text{CO}_2\text{R}^{\text{VII}-14}$ groups;

het^{VII} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{VII} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, $\text{CO}_2\text{R}^{\text{VII}-14}$, CF_3 , $\text{C}_{1-6}\text{alkoxy}$, oxo, oxime, and $\text{C}_{1-6}\text{alkyl}$ which may be further substituted by one to three $\text{SR}^{\text{VII}-14}$, $\text{NR}^{\text{VII}-14}\text{R}^{\text{VII}-14}$, $\text{OR}^{\text{VII}-14}$, or $\text{CO}_2\text{R}^{\text{VII}-14}$ groups;

wherein Formula VIII is



and pharmaceutically acceptable salts thereof,
wherein

A^{VIII} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO₂, or
- e) F;

R^{VIII-1} is

- a) R^{VIII-5},
- b) NR^{VIII-7}R^{VIII-8}, or
- c) SO₂R^{VIII-9};

R^{VIII-2} is

- a) aryl^{VIII},
- b) het^{VIII},
- c) SO_mR^{VIII-6},
- d) OC₂₋₇ alkyl substituted by OH,
- e) SC₂₋₇ alkyl substituted by OH, or
- f) C₂₋₈ alkyl which is partially unsaturated and is optionally substituted by one or more substituents selected from R^{VIII-11}, OR^{VIII-13}, SR^{VIII-13}, NR^{VIII-7}R^{VIII-8}, halo, (C=O)C₁₋₇ alkyl or SO_m^{VIII}R^{VIII-9};

with the proviso that when R^{VIII-1} = R^{VIII-5} =

(CH₂CH₂O)_i^{VIII}R^{VIII-10}, then R^{VIII-2} may additionally represent

- a) H,
- b) halo,
- c) (C=O)R^{VIII-6},

- d) $(C=O)OR^{VIII-9}$,
- e) cyano,
- f) $OR^{VIII-10}$,
- g) het^{VIII} ,
- h) $NR^{VIII-7}R^{VIII-8}$,
- i) $SR^{VIII-10}$,
- j) het^{VIII} ,
- k) $NHCOR^{VIII-12}$,
- l) $NHSO_2R^{VIII-12}$, or
- m) R^{VIII-2} together with R^{VIII-3} or R^{VIII-4} form a carbocyclic or het^{VIII} which may be optionally substituted by $NR^{VIII-7}R^{VIII-8}$, or C_{1-7} alkyl which may be optionally substituted by $OR^{VIII-14}$;

R^{VIII-3} and R^{VIII-4} are independently:

- a) H,
- b) halo,
- c) $aryl^{VIII}$,
- d) $S(O)_mR^{VIII-6}$,
- e) $(C=O)R^{VIII-6}$,
- f) $(C=O)OR^{VIII-9}$,
- g) cyano,
- h) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom,
- i) $OR^{VIII-10}$,
- j) $Ohet^{VIII}$,
- k) $NR^{VIII-7}R^{VIII-8}$,
- l) $SR^{VIII-10}$,
- m) $Shet^{VIII}$,
- n) $NHCOR^{VIII-12}$,
- o) $NHSO_2R^{VIII-12}$,
- p) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more

substituents of the group $R^{VIII-11}$, $OR^{VIII-13}$, $SR^{VIII-10}$, $SR^{VIII-13}$, $NR^{VIII-7}R^{VIII-8}$, halo, $(C=O)C_{1-7}$ alkyl, or $SO_m^{VIII}R^{VIII-9}$, or

- q) R^{VIII-4} together with R^{VIII-3} form a carbocyclic or het which may be optionally substituted by $NR^{VIII-7}R^{VIII-8}$, or C_{1-7} alkyl which may be optionally substituted by $OR^{VIII-14}$;

R^{VIII-5} is

- a) $(CH_2CH_2O)_iR^{VIII-10}$,
- b) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom,
- c) $aryl^{VIII}$,
- d) C_{1-7} alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $NR^{VIII-7}R^{VIII-8}$, $R^{VIII-11}$, SO_mR^{VIII-9} , or OC_{2-4} alkyl which may be further substituted by het^{VIII} , $OR^{VIII-10}$, or $NR^{VIII-7}R^{VIII-8}$, or
- e) C_{3-8} cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from $R^{VIII-11}$, $NR^{VIII-7}R^{VIII-8}$, $SO_m^{VIII}R^{VIII-9}$, or C_{1-7} alkyl optionally substituted by $R^{VIII-11}$, $NR^{VIII-7}R^{VIII-8}$, or $SO_m^{VIII}R^{VIII-9}$;

R^{VIII-6} is

- a) C_{1-7} alkyl,
- b) $NR^{VIII-7}R^{VIII-8}$,
- c) $aryl^{VIII}$, or
- d) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom;

R^{VIII-7} and R^{VIII-8} are independently

- a) H,

- b) aryl^{VIII},
- c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR^{VIII-10}R^{VIII-10}, R^{VIII-11}, SO_m^{VIII}R^{VIII-9}, CONR^{VIII-10}R^{VIII-10}, or halo, or,
- d) R^{VIII-7} and R^{VIII-8} together with the nitrogen to which they are attached form a het^{VIII};

R^{VIII-9} is

- a) aryl^{VIII},
- b) het^{VIII},
- c) C₃₋₈cycloalkyl,
- d) methyl, or
- e) C₂₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR^{VIII-10}R^{VIII-10}, R^{VIII-11}, SH, CONR^{VIII-10}R^{VIII-10}, or halo;

R^{VIII-10} is

- a) H,
- b) methyl, or
- c) C₂₋₇alkyl optionally substituted by OH;

R^{VIII-11} is

- a) OR^{VIII-10},
- b) Ohet^{VIII},
- c) Oaryl^{VIII},
- d) CO₂R^{VIII-10},
- e) het^{VIII},
- f) aryl^{VIII}, or
- g) CN;

R^{VIII-12} is

- a) H,

- b) het^{VIII} ,
- c) $\text{aryl}^{\text{VIII}}$,
- d) $\text{C}_{3-8}\text{cycloalkyl}$,
- e) methyl, or
- f) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$ or $\text{R}^{\text{VIII}-11}$;

$\text{R}^{\text{VIII}-13}$ is

- a) $(\text{P}=\text{O})(\text{OR}^{14})_2$,
- b) $\text{CO}(\text{CH}_2)_n^{\text{VIII}}\text{CON}(\text{CH}_3) - (\text{CH}_2)_n^{\text{VIII}}\text{SO}_3^-\text{M}^+$,
- c) an amino acid,
- d) $\text{C}(=\text{O})\text{aryl}^{\text{VIII}}$, or
- e) $\text{C}(=\text{O})\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, $\text{aryl}^{\text{VIII}}$, het^{VIII} , CO_2H , or $\text{O}(\text{CH}_2)_n^{\text{VIII}}\text{CO}_2\text{R}^{\text{VIII}-14}$;

$\text{R}^{\text{VIII}-14}$ is

- a) H, or
- b) $\text{C}_{1-7}\text{alkyl}$;

each i^{VIII} is independently 2, 3, or 4;

each n^{VIII} is independently 1, 2, 3, 4 or 5;

each m^{VIII} is independently 0, 1, or 2;

M^{VIII} is sodium, potassium, or lithium;

$\text{aryl}^{\text{VIII}}$ is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;


wherein any $\text{aryl}^{\text{VIII}}$ is optionally substituted with one or more substituents selected from halo, OH, cyano, $\text{CO}_2\text{R}^{\text{VIII}-14}$, CF_3 , $\text{C}_{1-6}\text{alkoxy}$, and $\text{C}_{1-6}\text{alkyl}$ which may be further substituted by one to three $\text{SR}^{\text{VIII}-14}$, $\text{NR}^{\text{VIII}-14}\text{R}^{\text{VIII}-14}$, $\text{OR}^{\text{VIII}-14}$, or $\text{CO}_2\text{R}^{\text{VIII}-14}$ groups;

het^{VIII} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the

group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{VIII} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, $\text{CO}_2\text{R}^{\text{VIII}-14}$, CF_3 , C_{1-6} alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three $\text{SR}^{\text{VIII}-14}$, $\text{NR}^{\text{VIII}-14}\text{R}^{\text{VIII}-14}$, $\text{OR}^{\text{VIII}-14}$, or $\text{CO}_2\text{R}^{\text{VIII}-14}$ groups;

wherein Formula IX is



IX

and pharmaceutically acceptable salts thereof, wherein,

$\text{R}^{\text{IX}-1}$ is

- a) Cl,
- b) Br,
- c) CN,
- d) NO_2 , or
- e) F;

$\text{R}^{\text{IX}-2}$, $\text{R}^{\text{IX}-3}$ and $\text{R}^{\text{IX}-4}$ are independently selected from:

- a) H,
- b) halo,
- c) aryl^{IX} ,
- d) $\text{S}(\text{O})_m^{\text{IX}}\text{R}^{\text{IX}-6}$,
- e) $(\text{C}=\text{O})\text{R}^{\text{IX}-6}$,
- f) $(\text{C}=\text{O})\text{OR}^{\text{IX}-9}$,
- g) cyano,
- h) het^{IX} , wherein said IX-het is bound via a carbon atom,

- i) $\text{OR}^{\text{IX}-10}$,
- j) Ohet^{IX} ,
- k) $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$
- l) $\text{SR}^{\text{IX}-10}$,
- m) Shet^{IX} ,
- n) $\text{NHCOR}^{\text{IX}-12}$,
- o) $\text{NHSO}_2\text{R}^{\text{IX}-12}$, or
- p) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{IX}-11}$, $\text{OR}^{\text{IX}-13}$, $\text{SR}^{\text{IX}-10}$, $\text{SR}^{\text{IX}-13}$, $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}$ alkyl, or $\text{SO}_m^{\text{IX}}\text{R}^{\text{IX}-9}$;

$\text{R}^{\text{IX}-6}$ is

- a) C_{1-7} alkyl,
- b) $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$,
- c) aryl^{IX}, or
- d) het^{IX}, wherein said het^{IX} is bound via a carbon atom;

$\text{R}^{\text{IX}-7}$ and $\text{R}^{\text{IX}-8}$ are independently

- a) H,
- b) aryl^{IX},
- c) C_{1-7} alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, $\text{R}^{\text{IX}-11}$, $\text{SO}_m\text{R}^{\text{IX}-9}$, $\text{CONR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, or halo, or,
- d) $\text{R}^{\text{IX}-7}$ and $\text{R}^{\text{IX}-8}$ together with the nitrogen to which they are attached form a ^{IX}-het;

$\text{R}^{\text{IX}-9}$ is

- a) aryl^{IX},
- b) het^{IX},
- c) C_{3-8} cycloalkyl,
- d) methyl, or

- e) C₂₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR^{IX-10}R^{IX-10}, R^{IX-11}, SH, CONR^{IX-10}R^{IX-10}, or halo;

R^{IX-10} is

- a) H,
b) methyl, or
c) C₂₋₇alkyl optionally substituted by OH;

R^{IX-11} is

- a) OR^{IX-10},
b) Ohet^{IX},
c) Oaryl^{IX},
d) CO₂R^{IX-10},
e) het^{IX},
f) aryl^{IX}, or
g) CN;

R^{IX-12} is

- a) H,
b) het^{IX},
c) aryl^{IX},
d) C₃₋₈cycloalkyl,
e) methyl, or
f) C₂₋₇alkyl optionally substituted by NR^{IX-7}R^{IX-8} or R^{IX-11};

R^{IX-13} is

- a) (P=O) (OR^{IX-14})₂,
b) CO(CH₂)_n^{IX}CON(CH₃) - (CH₂)_n^{IX}SO₃⁻M^{IX+},
c) an amino acid,
d) C(=O)aryl^{IX}, or
e) C(=O)C₁₋₇alkyl optionally substituted by NR^{IX-7}R^{IX-8}, aryl^{IX}, het^{IX}, CO₂H, or O(CH₂)_nCO₂R^{IX-14};

R^{IX-14} is

a) H, or

b) C₁₋₇alkyl;

each n^{IX} is independently 1, 2, 3, 4 or 5;

each m^{IX} is independently 0, 1, or 2;

M^{IX} is sodium, potassium, or lithium;


aryl^{IX} is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

wherein any aryl^{IX} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, CO₂R^{IX-14}, CF₃, C₁₋₆alkoxy, and C₁₋₆alkyl which may be further substituted by one to three SR^{IX-14}, NR^{IX-14}R^{IX-14}, OR^{IX-14}, or CO₂R^{IX-14} groups;

het^{IX} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{IX} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO₂R^{IX-14}, CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆alkyl which may be further substituted by one to three SR^{IX-14}, NR^{IX-14}R^{IX-14}, OR^{IX-14}, or CO₂R^{IX-14} groups.

2. The method of claim 1, wherein the compound administered has the Formula



or a pharmaceutically acceptable salt thereof,
wherein,

A^{VI} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO₂, or
- e) F;

R^{VI-1} is

- a) R^{VI-5} , or
- b) SO₂ R^{VI-9}

R^{VI-2} , R^{VI-3} and R^{VI-4} may be the same or different and are selected from the group consisting of:

- a) H,
- b) halo,
- c) aryl^{VI},
- d) S(O)_m^{VI} R^{VI-6} ,
- e) (C=O) R^{VI-6} ,
- f) (C=O)OR^{VI-9},
- g) cyano,
- h) het^{VI}, wherein said het^{VI} is bound via a carbon atom,
- i) OR^{VI-10},
- j) Ohet^{VI},
- k) NR^{VI-7} R^{VI-8}
- l) SR^{VI-10},

- m) Shet^{VI} ,
- n) $\text{NHCOR}^{\text{VI-12}}$,
- o) $\text{NHSO}_2\text{R}^{\text{VI-12}}$,
- p) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{VI-11}}$, $\text{OR}^{\text{VI-13}}$, $\text{SR}^{\text{VI-10}}$, $\text{SR}^{\text{VI-13}}$, $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}\text{alkyl}$, or $\text{SO}_m^{\text{VI}}\text{R}^{\text{VI-9}}$, and
- q) $\text{R}^{\text{VI-3}}$ together with $\text{R}^{\text{VI-2}}$ or $\text{R}^{\text{VI-4}}$ form a carbocyclic or het^{VI} which may be optionally substituted by $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, or $\text{C}_{1-7}\text{alkyl}$ which may be optionally substituted by $\text{OR}^{\text{VI-14}}$;

$\text{R}^{\text{VI-5}}$ is

- a) $(\text{CH}_2\text{CH}_2\text{O})_i\text{R}^{\text{VI-10}}$,
- b) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, $\text{R}^{\text{VI-11}}$, $\text{SO}_m^{\text{VI}}\text{R}^{\text{VI-9}}$, or $\text{OC}_{2-4}\text{alkyl}$ which may be further substituted by het^{VI} , $\text{OR}^{\text{VI-10}}$, or $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, or
- c) $\text{C}_{3-8}\text{cycloalkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of $\text{R}^{\text{VI-11}}$, $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, $\text{SO}_m^{\text{VI}}\text{R}^{\text{VI-9}}$, or $\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{R}^{\text{VI-11}}$, $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$, or $\text{SO}_m^{\text{VI}}\text{R}^{\text{VI-9}}$;

$\text{R}^{\text{VI-6}}$ is

- a) $\text{C}_{1-7}\text{alkyl}$,
- b) $\text{NR}^{\text{VI-7}}\text{R}^{\text{VI-8}}$,
- c) aryl^{VI} , or
- d) het^{VI} , wherein said het^{VI} is bound via a carbon atom;

$\text{R}^{\text{VI-7}}$ and $\text{R}^{\text{VI-8}}$ are independently

- a) H,
- b) aryl^{VI} ,

- c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of aryl^{VI}, NR^{VI-10}R^{VI-10}, R^{VI-11}, SO_m^{VI}R^{VI-9}, CONR^{VI-10}R^{VI-10}, or halo, or;
- d) C₃₋₈cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of R^{VI-11}, NR^{VI-7}R^{VI-8}, SO_m^{VI}R^{VI-9}, or C₁₋₇alkyl optionally substituted by R^{VI-11}, NR^{VI-7}R^{VI-8}, or SO_m^{VI}R^{VI-9}, or
- e) R^{VI-7} and R^{VI-8} together with the nitrogen to which they are attached form a het^{VI};

R^{VI-9} is

- a) aryl^{VI},
- b) het^{VI},
- c) C₃₋₈cycloalkyl,
- d) methyl, or
- e) C₂₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from a group consisting of NR^{VI-10}R^{VI-10}, R^{VI-11}, SH, CONR^{VI-10}R^{VI-10}, or halo;

R^{VI-10} is

- a) H,
- b) methyl, or
- c) C₂₋₇alkyl optionally substituted by OH;

R^{VI-11} is

- a) OR¹⁰,
- b) Ohet^{VI},
- c) Oaryl^{VI},
- d) CO₂R¹⁰,
- e) het^{VI},
- f) aryl^{VI},
- g) CN, or

- h) C₃₋₈cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of R^{VI-11}, NR^{VI-7}R^{VI-8}, SO_m^{VI}R^{VI-9}, or C₁₋₇alkyl optionally substituted by R^{VI-11}, NR^{VI-7} R^{VI-8}, or SO_m^{VI}R^{VI-9};

R^{VI-12} is

- a) H,
- b) het^{VI},
- c) aryl^{VI},
- d) C₃₋₈cycloalkyl,
- e) methyl, or
- f) C₂₋₇alkyl optionally substituted by NR^{VI-7}R^{VI-8} or R^{VI-11};

R^{VI-13} is

- a) (P=O) (OR^{VI-14})₂,
- b) CO(CH₂)_n^{VI}CON(CH₃) - (CH₂)_nSO₃⁻M^{VI+},
- c) an amino acid,
- d) C(=O)aryl^{VI},
- e) C(=O)C₁₋₇alkyl optionally substituted by NR^{VI-7} R^{VI-8}, aryl^{VI}, het^{VI}, CO₂H, or O(CH₂)_n^{VI}CO₂R^{VI-14}, or
- f) C(=O)NR^{VI-7}R^{VI-8}

R^{VI-14} is

- a) H, or
- b) C₁₋₇alkyl;

each i^{VI} is independently 2, 3, or 4;

each n^{VI} is independently 1, 2, 3, 4 or 5;

each m^{VI} is independently 0, 1, or 2;

M^{VI} is sodium, potassium, or lithium;

aryl^{VI} is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

wherein any aryl^{VI} is optionally substituted with one or

more substituents selected from the group consisting of halo, OH, cyano, $\text{CO}_2\text{R}^{\text{VI}-14}$, CF_3 , C_{1-6} alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three $\text{SR}^{\text{VI}-14}$, $\text{NR}^{\text{VI}-14}\text{R}^{\text{VI}-14}$, $\text{OR}^{\text{VI}-14}$, or $\text{CO}_2\text{R}^{\text{VI}-14}$;

het^{VI} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{VI} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, $\text{CO}_2\text{R}^{\text{VI}-14}$, CF_3 , C_{1-6} alkoxy, oxo, oxime, and C_{1-6} alkyl which maybe further substituted by one to three $\text{SR}^{\text{VI}-14}$, $\text{NR}^{\text{VI}-14}\text{R}^{\text{VI}-14}$, $\text{OR}^{\text{VI}-14}$, or $\text{CO}_2\text{R}^{\text{VI}-14}$.

3. The method of Claim 2, wherein A^{VI} is Cl.

4. The method of Claim 2, wherein the compound administered is selected from the group consisting of

N-(4-chlorobenzyl)-6-iodo-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide; N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(hydroxymethyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-hydroxy-1-butynyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide; N-(4-

chlorobenzyl)-8-[(1R,2R)-1-hydroxy-2-methylcyclohexyl]ethynyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(cyclopropylethynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-4-oxo-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butynyl}-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(4-hydroxy-1-butynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(1-hydroxycyclohexyl)ethynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3,3-dicyclopropyl-3-hydroxy-1-propynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3S)-3-hydroxy-1-butynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

8-{3-[(aminocarbonyl)amino]-3-methyl-1-butynyl}-N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-8-[3-methyl-3-(4-thioxo-1,3,5-triazinan-1-yl)-1-butynyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3R)-3-hydroxy-1-butynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butynyl}-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(5-hydroxy-1-pentynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[[(1R,2S)-2-hydroxycyclopentyl]ethynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-3-methyl-1-butynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(4,5-dichloro-1H-imidazol-1-yl)-1-propynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propynyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-4-oxo-8-(phenylethynyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-3-phenyl-1-propynyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propynyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(4-hydroxy-1-butynyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propynyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(4-hydroxy-1-butynyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propynyl]-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[3-(methylsulfonyl)propyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[3-(methylsulfanyl)propyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[(2-hydroxyethoxy)methyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-tetrahydro-3-furanyl-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-(1,2-diethyl-4-pyrazolidinyl)-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-1-(3-oxetanyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-{3-[3-(3-hydroxypropyl)sulfonyl]propyl}-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[2-(2-ethoxyethoxy)ethyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-[(phenylsulfinyl)methyl]-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-[(phenylsulfonyl)methyl]-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-
[(phenylsulfanyl)methyl]-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-
tetrahydro-2H-pyran-3-yl-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[(methylsulfanyl)methyl]-6-(4-
morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-[[(4-chlorophenyl) sulfinyl]methyl]-
6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-
tetrahydro-2H-pyran-4-yl-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-
oxo-8-(4-thiomorpholinylmethyl)-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(4-hydroxy-1-piperidinyl)methyl]-1-
methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-{ [(3R)-3-
hydroxypyrrolidinyl]methyl}-1-methyl-6-(4-
morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3-hydroxy-1-piperidinyl)methyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

[3-{[(4-chlorobenzyl)amino]carbonyl}-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-8-cinnolinyl]methyl 4-morpholinecarboxylate;

N-(4-chlorobenzyl)-8-(hydroxymethyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3-cyanobenzyl)amino]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6,8-bis(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

8-[(1-acetyl-4-piperidinyl)amino]-N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-8-{[1-methyl-2-(phenylsulfonyl)ethyl]amino}-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-{[3-(4-methoxyphenyl)-1-methylpropyl]amino}-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

8-amino-N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-8-
[(3-nitrobenzyl)amino]-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-
oxo-8-(tetrahydro-2H-pyran-4-ylamino)-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(3-hydroxy-1-propyl)-1-methyl-4-oxo-
1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-6-(4-hydroxy-1-butyl)-1-methyl-4-oxo-
1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-{[(1R,2R)-1-hydroxy-2-
methylcyclohexyl]ethyl}-1-methyl-4-oxo-6-(tetrahydro-2H-
pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(cyclopropylethyl)-1-methyl-6-(4-
morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propyl]-1-
methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-4-oxo-8-{4-[(4R)-2-oxo-1,3-
oxazolidin-4-yl]-1-butyl}-6-(tetrahydro-2H-pyran-4-
ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(4-hydroxy-1-butyl)-1-methyl-6-(4-
morpholinylmethyl)-4-oxo-1,4-dihydro-3-
cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(1-hydroxycyclohexyl)ethyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3,3-dicyclopropyl-3-hydroxy-1-propyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3S)-3-hydroxy-1-butyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

8-{3-[(aminocarbonyl)amino]-3-methyl-1-butyl}-N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-8-[3-methyl-3-(4-thioxo-1,3,5-triazinan-1-yl)-1-butyl]-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[(3R)-3-hydroxy-1-butyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butyl}-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(5-hydroxy-1-pentyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-{{(1R,2S)-2-hydroxycyclopentyl}ethyl}-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-3-methyl-1-butyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(4,5-dichloro-1H-imidazol-1-yl)-1-propyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1H-imidazol-1-yl)-1-propyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1H-imidazol-1-yl)-1-propynyl]-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propyl)-1-methyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-4-oxo-8-(phenylethyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-3-phenyl-1-propyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(4-hydroxy-1-butyl)-1-methyl-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3-hydroxy-1-propyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;


N-(4-chlorobenzyl)-8-(4-hydroxy-1-butyl)-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propyl]-1-methyl-4-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1,4-dihydro-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-1-methyl-8-{[methyl(tetrahydro-2-furanylmethyl)amino]methyl}-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro-3-cinnolinecarboxamide;

and pharmaceutically acceptable salts thereof.

5. The method of Claim 1, wherein the compound administered has the Formula VII



VII

or a pharmaceutically acceptable salt thereof,
wherein,
A^{VII} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO₂, or
- e) F;

R^{VII-1} is

- a) aryl^{VII},
- b) S(O)_m^{VII}R^{VII-6},
- c) (C=O)R^{VII-6}, with the proviso that if R^{VII-6} is NR^{VII-7}R^{VII-8}, then R^{VII-7} and R^{VII-8} do not both equal H
- d) (C=O)OR^{VII-9},
- e) cyano,
- f) het^{VII}, wherein said het^{VII} is bound via a carbon atom,
- g) Ohet^{VII},
- h) NR^{VII-7}R^{VII-8} with the proviso that R^{VII-7} and R^{VII-8} do not both equal H
- i) SR^{VII-10},
- j) Shet^{VII},
- k) NHCOR^{VII-12},
- l) NHSO₂R^{VII-12},
- m) C₁₋₇alkyl which is partially unsaturated and optionally substituted by one or more substituents of the group R^{VII-11}, OR^{VII-13}, SR^{VII-10}, SR^{VII-13}, NR^{VII-7}R^{VII-8}, halo, (C=O)C₁₋₇alkyl, or SO_mR^{VII-9}, or
- n) C₁₋₇alkyl which is substituted by one or more substituents of the group R^{VII-11}, OR^{VII-13}, SR^{VII-10}, SR^{VII-13}, NR^{VII-7}R^{VII-8}, halo, (C=O)C₁₋₇alkyl, or SO_mR^{VII-9};

R^{VII-2} is

- a) H,
- b) halo,
- c) aryl^{VII},

- d) $S(O)_m R^{VII-6}$,
- e) $(C=O)R^{VII-6}$,
- f) $(C=O)OR^{VII-9}$,
- g) cyano,
- h) het^{VII} , wherein said het^{VII} is bound via a carbon atom,
- i) OR^{VII-10} ,
- j) $Ohet^{VII}$,
- k) $NR^{VII-7}R^{VII-8}$,
- l) SR^{VII-10} ,
- m) $Shet^{VII}$,
- n) $NHCOR^{VII-12}$,
- o) $NHSO_2R^{VII-12}$, or
- p) $C_{1-7}alkyl$ which may be partially unsaturated and optionally substituted by one or more substituents of the group R^{VII-11} , OR^{VII-13} , SR^{VII-10} , SR^{VII-13} , $NR^{VII-7}R^{VII-8}$, halo, $(C=O)C_{1-7}alkyl$, or $SO_m R^{VII-9}$, or
- q) R^{VII-1} together with R^{VII-2} form a carbocyclic or het^{VII} which may be optionally substituted by $NR^{VII-7}R^{VII-8}$, or $C_{1-7}alkyl$ which may be optionally substituted by OR^{VII-14} ;

R^{VII-6} is

- a) $C_{1-7}alkyl$,
- b) $NR^{VII-7}R^{VII-8}$
- c) $aryl^{VII}$, or
- d) het^{VII} , wherein said het^{VII} is bound via a carbon atom;

R^{VII-7} and R^{VII-8} are independently

- a) H,
- b) $aryl^{VII}$,
- c) $C_{1-7}alkyl$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $NR^{VII-10}R^{VII-10}$, R^{VII-11} , $SO_m R^{VII-9}$, $CONR^{VII-10}R^{VII-10}$, or halo, or,

- d) R^{VII-7} and R^{VII-8} together with the nitrogen to which they are attached form a het^{VII} ;

R^{VII-9} is

- a) $aryl^{VII}$,
- b) het^{VII} ,
- c) $C_{3-8}cycloalkyl$,
- d) methyl, or
- e) $C_{2-7}alkyl$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $NR^{VII-10}R^{VII-10}$, R^{VII-11} , SH , $CONR^{VII-10}R^{VII-10}$, or halo;

R^{VII-10} is

- a) H ,
- b) methyl, or
- c) $C_{2-7}alkyl$ optionally substituted by OH ;

R^{VII-11} is

- a) OR^{VII-10} ,
- b) $Ohet^{VII}$,
- c) $Oaryl^{VII}$,
- d) CO_2R^{VII-10} ,
- e) het^{VII} ,
- f) $aryl^{VII}$,
- g) CN , or
- h) $C_{3-8}cycloalkyl$ which may be partially unsaturated and optionally substituted by one or more substituents selected from a group consisting of R^{VII-11} , $NR^{VII-7}R^{VII-8}$, $SO_m^{VII}R^{VII-9}$, or $C_{1-7}alkyl$ optionally substituted by R^{VII-11} , $NR^{VII-7}R^{VII-8}$, or $SO_m^{VII}R^{VII-9}$;

R^{VII-12} is

- a) H ,
- b) het^{VII} ,
- c) $aryl^{VII}$,
- d) $C_{3-8}cycloalkyl$,
- e) methyl, or

- f) C₂₋₇alkyl optionally substituted by NR^{VII-7}R^{VII-8}
or R^{VII-11};

R^{VII-13} is

- a) (P=O) (OR^{VII-14})₂,
b) CO(CH₂)_n^{VII}CON(CH₃) - (CH₂)_nSO₃^{-VII+},
c) an amino acid,
d) C(=O)aryl^{VII}, or
e) C(=O)C₁₋₇alkyl optionally substituted by
NR^{VII-7}R^{VII-8}, aryl^{VII}, het^{VII}, CO₂H, or
O(CH₂)_n^{VII}CO₂R^{VII-14};

R^{VII-14} is

- a) H, or
b) C₁₋₇alkyl;

each n^{VII} is independently 1, 2, 3, 4 or 5;

each m^{VII} is independently 0, 1, or 2;

M^{VII} is sodium, potassium, or lithium;

aryl^{VII} is a phenyl radical or an ortho-fused bicyclic
carbocyclic radical wherein at least one ring is
aromatic;

wherein any aryl^{VII} is optionally substituted with one or
more substituents selected from the group consisting
of halo, OH, cyano, CO₂R^{VII-14}, CF₃, C₁₋₆alkoxy, and C₁₋₆
alkyl which may be further substituted by one to
three SR^{VII-14}, NR^{VII-14}R^{VII-14}, OR^{VII-14}, or CO₂R^{VII-14}
groups;

het^{VII} is a four- (4), five- (5), six- (6), or seven- (7)
membered saturated or unsaturated heterocyclic ring
having 1, 2, or 3 heteroatoms selected from the
group consisting of oxygen, sulfur, and nitrogen,
which is optionally fused to a benzene ring, or any
bicyclic heterocycle group;

wherein any het^{VII} is optionally substituted with one or
more substituents selected from the group consisting
of halo, OH, cyano, phenyl, CO₂R^{VII-14}, CF₃, C₁₋₆alkoxy,
oxo, oxime, and C₁₋₆ alkyl which may be further

substituted by one to three $\text{SR}^{\text{VII-14}}$, $\text{NR}^{\text{VII-14}}\text{R}^{\text{VII-14}}$, $\text{OR}^{\text{VII-14}}$, or $\text{CO}_2\text{R}^{\text{VII-14}}$ groups.

6. The method of Claim 5, wherein A^{VII} is Cl.

7. The method of Claim 6, wherein $\text{R}^{\text{VII-1}}$ is selected from the group consisting of CH_2 -morpholine, alkynyl- CH_2OH , CH_2 -(tetrahydro-2H-pyran-4-yl) and $(\text{CH}_2)_3\text{OH}$.

8. The compound of Claim 6, wherein the compound administered is selected from the group consisting of

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

Methyl 3-{[(4-chlorobenzyl)amino]carbonyl}-4-hydroxy-6-cinnolinecarboxylate;

N-(4-chlorobenzyl)-4-hydroxy-6-(hydroxymethyl)-3-cinnolinecarboxamide N-(4-chlorobenzyl)-8-(cyclopropylethynyl)-4-hydroxy-6-

(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propynyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(4-hydroxy-1-butyryl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(1-hydroxycyclohexyl)ethynyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3,3-dicyclopropyl-3-hydroxy-1-propynyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(3S)-3-hydroxy-1-butynyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

8-{3-[(aminocarbonyl)amino]-3-methyl-1-butynyl}-N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[3-methyl-3-(4-thioxo-1,3,5-triazinan-1-yl)-1-butynyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(3R)-3-hydroxy-1-butynyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butynyl}-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propynyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(5-hydroxy-1-pentynyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-([(1R,2S)-2-hydroxycyclopentyl]ethynyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-3-methyl-1-butynyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(4,5-dichloro-1H-imidazol-1-yl)-1-propynyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-1-propynyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(cyclopropylethyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(4-hydroxy-1-butyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(1-hydroxycyclohexyl)ethyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-(3,3-dicyclopropyl-3-hydroxy-1-propyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(3S)-3-hydroxy-1-butyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

8-{3-[(aminocarbonyl)amino]-3-methyl-1-butyl}-N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[3-methyl-3-(4-thioxo-1,3,5-triazinan-1-yl)-1-butyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(3R)-3-hydroxy-1-butyl]-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butyl}-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(1,1-dioxido-4-thiomorpholinyl)-1-propyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(5-hydroxy-1-pentyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-{[(1R,2S)-2-hydroxycyclopentyl]ethyl}-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-3-methyl-1-butyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(4,5-dichloro-1H-imidazol-1-yl)-1-propyl]-4-hydroxy-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-1-propyl)-6-(4-morpholinylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-1-propynyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(4-hydroxy-1-butynyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-1-propynyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(phenylethynyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-3-phenyl-1-propynyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(4-hydroxy-1-butynyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propynyl]-4-hydroxy-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-{[(1R,2R)-1-hydroxy-2-methylcyclohexyl]ethynyl}-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butynyl}-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-1-propyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(phenylethyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(3-hydroxy-3-phenyl-1-propyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-(4-hydroxy-1-butyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;


N-(4-chlorobenzyl)-8-[3-(dimethylamino)-1-propyl]-4-hydroxy-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-[(1R,2R)-1-hydroxy-2-methylcyclohexyl]ethyl)-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-8-{4-[(4R)-2-oxo-1,3-oxazolidin-4-yl]-1-butyl}-6-(tetrahydro-2H-pyran-4-ylmethyl)-3-cinnolinecarboxamide;

and pharmaceutically acceptable salts thereof.

9. A method of Claim 1, wherein the compound administered is Formula VIII



and pharmaceutically acceptable salts thereof, wherein A^{VIII} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO₂, or
- e) F;

R^{VIII-1} is

- a) R^{VIII-5},
- b) NR^{VIII-7}R^{VIII-8}, or
- c) SO₂R^{VIII-9};

R^{VIII-2} is

- a) aryl^{VIII},
- b) het^{VIII},
- c) SO_m^{VIII}R^{VIII-6},
- d) OC₂₋₇ alkyl substituted by OH,
- e) SC₂₋₇ alkyl substituted by OH, or
- f) C₂₋₈ alkyl which is partially unsaturated and is optionally substituted by one or more substituents selected from R^{VIII-11}, OR^{VIII-13}, SR^{VIII-13}, NR^{VIII-7}R^{VIII-8}, halo, (C=O)C₁₋₇ alkyl or SO_m^{VIII}R^{VIII-9};

with the proviso that when R^{VIII-1} = R^{VIII-5} =

(CH₂CH₂O)_iR^{VIII-10}, then R^{VIII-2} may additionally represent

- a) H,
- b) halo,
- c) (C=O)R^{VIII-6},
- d) (C=O)OR^{VIII-9},
- e) cyano,
- f) OR^{VIII-10},
- g) Ohet^{VIII},
- h) NR^{VIII-7}R^{VIII-8},
- i) SR^{VIII-10},
- j) Shet^{VIII},
- k) NHCOR^{VIII-12},

- l) $\text{NHSO}_2\text{R}^{\text{VIII}-12}$, or
- m) $\text{R}^{\text{VIII}-2}$ together with $\text{R}^{\text{VIII}-3}$ or $\text{R}^{\text{VIII}-4}$ form a carbocyclic or het^{VIII} which may be optionally substituted by $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, or $\text{C}_{1-7}\text{alkyl}$ which may be optionally substituted by $\text{OR}^{\text{VIII}-14}$;

$\text{R}^{\text{VIII}-3}$ and $\text{R}^{\text{VIII}-4}$ are independently:

- a) H,
- b) halo,
- c) $\text{aryl}^{\text{VIII}}$,
- d) $\text{S}(\text{O})_m^{\text{VIII}}\text{R}^{\text{VIII}-6}$,
- e) $(\text{C}=\text{O})\text{R}^{\text{VIII}-6}$,
- f) $(\text{C}=\text{O})\text{OR}^{\text{VIII}-9}$,
- g) cyano,
- h) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom,
- i) $\text{OR}^{\text{VIII}-10}$,
- j) $\text{Ohet}^{\text{VIII}}$,
- k) $\text{R}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$,
- l) $\text{SR}^{\text{VIII}-10}$,
- m) $\text{Shet}^{\text{VIII}}$,
- n) $\text{NHCOR}^{\text{VIII}-12}$,
- o) $\text{NHSO}_2\text{R}^{\text{VIII}-12}$,
- p) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{VIII}-11}$, $\text{OR}^{\text{VIII}-13}$, $\text{SR}^{\text{VIII}-10}$, $\text{SR}^{\text{VIII}-13}$, $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}\text{alkyl}$, or $\text{SO}_m^{\text{VIII}}\text{R}^{\text{VIII}-9}$, or
- q) $\text{R}^{\text{VIII}-4}$ together with $\text{R}^{\text{VIII}-3}$ form a carbocyclic or het^{VIII} which may be optionally substituted by $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, or $\text{C}_{1-7}\text{alkyl}$ which may be optionally substituted by $\text{OR}^{\text{VIII}-14}$;

$\text{R}^{\text{VIII}-5}$ is

- a) $(\text{CH}_2\text{CH}_2\text{O})_i^{\text{VIII}}\text{R}^{\text{VIII}-10}$,
- b) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom,
- c) $\text{aryl}^{\text{VIII}}$,
- d) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, $\text{R}^{\text{VIII}-11}$, $\text{SO}_m^{\text{VIII}}\text{R}^{\text{VIII}-9}$, or $\text{OC}_{2-4}\text{alkyl}$ which may be further substituted by het^{VIII} , $\text{OR}^{\text{VIII}-10}$, or $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, or
- e) $\text{C}_{3-8}\text{cycloalkyl}$ which may be partially unsaturated and optionally substituted by one or more substituents selected from $\text{R}^{\text{VIII}-11}$, $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, $\text{SO}_m^{\text{VIII}}\text{R}^{\text{VIII}-9}$, or $\text{C}_{1-7}\text{alkyl}$ optionally substituted by $\text{R}^{\text{VIII}-11}$, $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$, or $\text{SO}_m\text{R}^{\text{VIII}-9}$;

$\text{R}^{\text{VIII}-6}$ is

- a) $\text{C}_{1-7}\text{alkyl}$,
- b) $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$,
- c) $\text{aryl}^{\text{VIII}}$, or
- d) het^{VIII} , wherein said het^{VIII} is bound via a carbon atom;

$\text{R}^{\text{VIII}-7}$ and $\text{R}^{\text{VIII}-8}$ are independently

- a) H,
- b) $\text{aryl}^{\text{VIII}}$,
- c) $\text{C}_{1-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{VIII}-10}\text{R}^{\text{VIII}-10}$, $\text{R}^{\text{VIII}-11}$, $\text{SO}_m\text{R}^{\text{VIII}-9}$, $\text{CONR}^{\text{VIII}-10}\text{R}^{\text{VIII}-10}$, or halo, or,
- d) $\text{R}^{\text{VIII}-7}$ and $\text{R}^{\text{VIII}-8}$ together with the nitrogen to which they are attached form a het^{VIII} ;

$\text{R}^{\text{VIII}-9}$ is

- a) $\text{aryl}^{\text{VIII}}$,

- b) het^{VIII} ,
- c) $\text{C}_{3-8}\text{cycloalkyl}$,
- d) methyl, or
- e) $\text{C}_{2-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{VIII}-10}\text{R}^{\text{VIII}-10}$, $\text{R}^{\text{VIII}-11}$, SH , $\text{CONR}^{\text{VIII}-10}\text{R}^{\text{VIII}-10}$, or halo;

$\text{R}^{\text{VIII}-10}$ is

- a) H,
- b) methyl, or
- c) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by OH;

$\text{R}^{\text{VIII}-11}$ is

- a) $\text{OR}^{\text{VIII}-10}$,
- b) $\text{Ohet}^{\text{VIII}}$,
- c) $\text{Oaryl}^{\text{VIII}}$,
- d) $\text{CO}_2\text{R}^{\text{VIII}-10}$,
- e) het^{VIII} ,
- f) $\text{aryl}^{\text{VIII}}$, or
- g) CN;

$\text{R}^{\text{VIII}-12}$ is

- a) H,
- b) het^{VIII} ,
- c) $\text{aryl}^{\text{VIII}}$,
- d) $\text{C}_{3-8}\text{cycloalkyl}$,
- e) methyl, or
- f) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{VIII}-7}\text{R}^{\text{VIII}-8}$ or $\text{R}^{\text{VIII}-11}$;

$\text{R}^{\text{VIII}-13}$ is

- a) $(\text{P}=\text{O})(\text{OR}^{14})_2$,
- b) $\text{CO}(\text{CH}_2)_n^{\text{VIII}}\text{CON}(\text{CH}_3) - (\text{CH}_2)_n\text{SO}_3^-\text{M}^{\text{VIII}+}$,
- c) an amino acid,
- d) $\text{C}(=\text{O})\text{aryl}^{\text{VIII}}$, or

e) $C(=O)C_{1-7}alkyl$ optionally substituted by
 $NR^{VIII-7}R^{VIII-8}$, $aryl^{VIII}$, het^{VIII} , CO_2H , or
 $O(CH_2)_n^{VIII}CO_2R^{VIII-14}$;

$R^{VIII-14}$ is

- a) H, or
- b) $C_{1-7}alkyl$;

each i^{VIII} is independently 2, 3, or 4;

each n^{VIII} is independently 1, 2, 3, 4 or 5;

each m^{VIII} is independently 0, 1, or 2;

M^{VIII} is sodium, potassium, or lithium;

$aryl^{VIII}$ is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

wherein any $aryl^{VIII}$ is optionally substituted with one or more substituents selected from halo, OH, cyano, $CO_2R^{VIII-14}$, CF_3 , $C_{1-6}alkoxy$, and $C_{1-6}alkyl$ which may be further substituted by one to three $SR^{VIII-14}$, $NR^{VIII-14}R^{VIII-14}$, $OR^{VIII-14}$, or $CO_2R^{VIII-14}$ groups;

het^{VIII} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;

wherein any het^{VIII} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, $CO_2R^{VIII-14}$, CF_3 , $C_{1-6}alkoxy$, oxo, oxime, and $C_{1-6}alkyl$ which may be further substituted by one to three $SR^{VIII-14}$, $NR^{VIII-14}R^{VIII-14}$, $OR^{VIII-14}$, or $CO_2R^{VIII-14}$ groups.

10. The method of Claim 9, wherein A^{VIII} is Cl.

11. The method of Claim 9, wherein R^{VIII-2} is alkynyl-CH₂OH.

12. The method of Claim 9, wherein the compound administered is N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-1,7-dimethyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide, or N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-7-methoxy-1-methyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide; or a pharmaceutically acceptable salt thereof.

13. The method of Claim 9, wherein the compound administered is:

N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-1,7-dimethyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-6-(3-hydroxypropyl)-1,7-dimethyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

N-(4-Chlorobenzyl)-6-iodo-7-methoxy-1-methyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-1,7-dimethyl-6-(4-morpholinylmethyl)-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-1-methyl-4,7-dioxo-1,4,7,8-tetrahydro[1,8]naphthyridine-3-carboxamide;


N-(4-chlorobenzyl)-6-(3-hydroxy-1-propynyl)-7-methoxy-1-methyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-6-(3-hydroxypropyl)-7-methoxy-1-methyl-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamide;

ethyl 6-([(4-chlorobenzyl)amino]carbonyl)-2-methoxy-8-methyl-5-oxo-5,8-dihydro[1,8]naphthyridine-3-carboxylate;

and pharmaceutically acceptable salts thereof.

14. A method of Claim 1, wherein the compound administered has the Formula IX



IX

and pharmaceutically acceptable salts thereof, wherein, R^{IX-1} is

- a) Cl,
- b) Br,
- c) CN,
- d) NO_2 , or
- e) F;

R^{IX-2} , R^{IX-3} and R^{IX-4} are independently selected from:

- a) H,
- b) halo,
- c) aryl^{IX},
- d) $S(O)_m R^{IX-6}$,
- e) $(C=O)R^{IX-6}$,
- f) $(C=O)OR^{IX-9}$,

- g) cyano,
- h) het^{IX} , wherein said het^{IX} is bound via a carbon atom,
- i) $\text{OR}^{\text{IX}-10}$,
- j) Ohet^{IX} ,
- k) $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$
- l) $\text{SR}^{\text{IX}-10}$,
- m) $\text{S}^{\text{IX}}\text{-het}$,
- n) $\text{NHCOR}^{\text{IX}-12}$,
- o) $\text{NHSO}_2\text{R}^{\text{IX}-12}$, or
- p) C_{1-7} alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group $\text{R}^{\text{IX}-11}$, $\text{OR}^{\text{IX}-13}$, $\text{SR}^{\text{IX}-10}$, $\text{SR}^{\text{IX}-13}$, $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$, halo, $(\text{C}=\text{O})\text{C}_{1-7}$ alkyl, or $\text{SO}_m\text{R}^{\text{IX}-9}$;

$\text{R}^{\text{IX}-6}$ is

- a) C_{1-7} alkyl,
- b) $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$,
- c) aryl^{IX}, or
- d) het^{IX} , wherein said het^{IX} is bound via a carbon atom;

$\text{R}^{\text{IX}-7}$ and $\text{R}^{\text{IX}-8}$ are independently

- a) H,
- b) aryl^{IX},
- c) C_{1-7} alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, $\text{R}^{\text{IX}-11}$, $\text{SO}_m\text{R}^{\text{IX}-9}$, $\text{CONR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, or halo, or,
- d) $\text{R}^{\text{IX}-7}$ and $\text{R}^{\text{IX}-8}$ together with the nitrogen to which they are attached form a het^{IX} ;

$\text{R}^{\text{IX}-9}$ is

- a) aryl^{IX},

- b) het^{IX} ,
- c) $\text{C}_{3-8}\text{cycloalkyl}$,
- d) methyl, or
- e) $\text{C}_{2-7}\text{alkyl}$ which may be partially unsaturated and is optionally substituted by one or more substituents selected from $\text{NR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, $\text{R}^{\text{IX}-11}$, SH , $\text{CONR}^{\text{IX}-10}\text{R}^{\text{IX}-10}$, or halo;

$\text{R}^{\text{IX}-10}$ is

- a) H,
- b) methyl, or
- c) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by OH;

$\text{R}^{\text{IX}-11}$ is

- a) $\text{OR}^{\text{IX}-10}$,
- b) Ohet^{IX} ,
- c) Oaryl^{IX} ,
- d) $\text{CO}_2\text{R}^{\text{IX}-10}$,
- e) het^{IX} ,
- f) aryl^{IX} , or
- g) CN;

$\text{R}^{\text{IX}-12}$ is

- a) H,
- b) het^{IX} ,
- c) aryl^{IX} ,
- d) $\text{C}_{3-8}\text{cycloalkyl}$,
- e) methyl, or
- f) $\text{C}_{2-7}\text{alkyl}$ optionally substituted by $\text{NR}^{\text{IX}-7}\text{R}^{\text{IX}-8}$ or $\text{R}^{\text{IX}-11}$;

$\text{R}^{\text{IX}-13}$ is

- a) $(\text{P}=\text{O})(\text{OR}^{\text{IX}-14})_2$,
- b) $\text{CO}(\text{CH}_2)_n^{\text{IX}}\text{CON}(\text{CH}_3) - (\text{CH}_2)_n^{\text{IX}}\text{SO}_3^-\text{M}^{\text{IX}+}$,
- c) an amino acid,
- d) $\text{C}(=\text{O})\text{aryl}$, or

e) $C(=O)C_{1-7}alkyl$ optionally substituted by $NR^{IX-7}R^{IX-8}$, $aryl^{IX}$, het^{IX} , CO_2H , or $O(CH_2)_nCO_2R^{IX-14}$;
 R^{IX-14} is

- H, or
- $C_{1-7}alkyl$;

each n^{IX} is independently 1, 2, 3, 4 or 5;
each m^{IX} is independently 0, 1, or 2;
 M^{IX} is sodium, potassium, or lithium;
 $aryl^{IX}$ is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any $aryl^{IX}$ is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, CO_2R^{IX-14} , CF_3 , $C_{1-6}alkoxy$, and $C_{1-6}alkyl$ which may be further substituted by one to three SR^{IX-14} , $NR^{IX-14}R^{IX-14}$, OR^{IX-14} , or CO_2R^{IX-14} groups;
 het^{IX} is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het^{IX} is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO_2R^{IX-14} , CF_3 , $C_{1-6}alkoxy$, oxo, oxime, and $C_{1-6}alkyl$ which may be further substituted by one to three SR^{IX-14} , $NR^{IX-14}R^{IX-14}$, OR^{IX-14} , or CO_2R^{IX-14} groups.

15. The method of Claim 14, wherein R^{IX-1} is Cl.

16. The method of Claim 14, wherein the compound administered is selected from a group consisting of

N-(4-chlorobenzyl)-4-hydroxy-7-methyl[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-7-methyl-6-(tetrahydro-2H-pyran-4-ylmethyl)[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-7-methyl-6-(4-morpholinylmethyl)[1,8]naphthyridine-3-carboxamide;

6-bromo-N-(4-chlorobenzyl)-4-hydroxy-7-methyl[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-7-methyl[1,8]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-iodo-7-methyl[1,8]naphthyridine-3-carboxamide; and

Methyl 6-{[(4-chlorobenzyl)amino]carbonyl}-5-hydroxy-2-methyl[1,8]naphthyridine-3-carboxylate.

17. The method according to Claim 1, wherein said mammal is a human.

18. The method according to Claim 1, wherein said mammal is a livestock or companion animal.

19. The method according to Claim 1, wherein the amount administered is from about 0.1 to about 300 mg/kg of mammal body weight.

20. The method according to Claim 1, wherein the amount administered is from about 1 to about 30 mg/kg of mammal body weight.

21. The method according to Claim 2, wherein the compound is administered parenterally, intravaginally, intranasally, topically, orally, or rectally.